Alector Follows Cassava With An Alzheimer’s Miss

AL002 failed across the board in a mid-stage study, and Alector has trimmed its workforce as it refocuses on its other two assets.

Tumbling blocks
AL002 Fails To Stand Up In Alzheimer's Studies • Source: Shutterstock

Another day, another Alzheimer’s failure. This time it is the turn of Alector, whose AbbVie-partnered anti-TREM2 antibody, AL002, failed in Phase II, and while this is not quite as big a catastrophe as befell Cassava on 25 November, it is bad enough. The company will lay off 17% of its staff as it refocuses on its remaining programs.

More from Clinical Trials

Epsilogen Hits Antibody Acquisition Trail With TigaTx Takeover

 
• By 

Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.

Aldeyra Expects Mid-2025 Refiling Of Reproxalap After Second CRL

 
• By 

Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.

Pipeline Watch: 13 Approvals And 13 Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Roche’s Brain Shuttle Delivers In Alzheimer’s, Moves Ahead To Phase III

 

By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.

More from Therapy Areas

Edgewise’s HCM Candidate May Provide Advantages Over BMS’s Camzyos

 
• By 

With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.

AbbVie On A STEAP Learning Curve In ADCs

 

Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.

Boehringer Still Sees Plenty Of Juice In Jardiance

 
• By 

Strong sales growth for the German group’s SGLT2 inhibitor in 2024